A combination of cationic liposome/green fluorescence protein (GFP)-p53 complexes and a chemotherapeutic drug, cisplatin was evaluated for therapeutic activity in human carcinoma cells. Cationic liposome/GFP-p53 complexes and cationic liposome/PEI 0.8K/GFP-p53 complexes were synthesized and evaluated in HeLa and in A549 cells for uptake and cytotoxicity, alone and in combination with cisplatin. The particle size of cationic liposome/GFP-p53 complexes and cationic liposome/PEI 0.8K/GFP-p53 complexes were 318±18 - 352±26 to 754±108 nm, and zeta potentials were -15.7±2.8 to +27±08 mV. The GFP expression upon the delivery by cationic liposome/pEGFP complexes and cationic liposome/PEI 0.8K/pEGFP complexes was demonstrated. Treatment of the cells with either cationic liposome/GFP-p53 complexes or cationic liposome/PEI 0.8K/GFP-p53 complexes inhibited cell growth. Upon post-treatment with cisplatin, the growth inhibition of the complexes was further increased in HeLa cells and significantly increased in A549 cells upon lipid-to-DNA ratio. This study concluded that the sensitivity to the cancer cells to cisplatin was dependent upon the cell line and the ratio of cationic liposome and GFP-p53. GFP-p53 expression delivered by cationic liposome/GFP-p53 complexes would be useful to increase the effect of cisplatin on the treatment of cancer cells.
Key words: cationic liposome, p53, polyethylenimine, growth inhibition, cisplatin, cancer
|
